Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33285097

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Jan
First author
Goldman JW

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Mar;22(3):e83. doi: 10.1016/S1470-2045(21)00008-5.
    note
    Source null
    related pmid
    33662291
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Mar;22(3):e84. doi: 10.1016/S1470-2045(21)00083-8.
    note
    Source null
    related pmid
    33662292
    relationship
    Comment in

Authors and identifiers

  1. name
    Goldman JW
    type
    Author
  2. name
    Dvorkin M
    type
    Author
  3. name
    Chen Y
    type
    Author
  4. name
    Reinmuth N
    type
    Author
  5. name
    Hotta K
    type
    Author
  6. name
    Trukhin D
    type
    Author
  7. name
    Statsenko G
    type
    Author
  8. name
    Hochmair MJ
    type
    Author
  9. name
    Özgüroğlu M
    type
    Author
  10. name
    Ji JH
    type
    Author
  11. name
    Garassino MC
    type
    Author
  12. name
    Voitko O
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Goldman JW
    type
    Author
  2. name
    Dvorkin M
    type
    Author
  3. name
    Chen Y
    type
    Author
  4. name
    Reinmuth N
    type
    Author
  5. name
    Hotta K
    type
    Author
  6. name
    Trukhin D
    type
    Author
  7. name
    Statsenko G
    type
    Author
  8. name
    Hochmair MJ
    type
    Author
  9. name
    Özgüroğlu M
    type
    Author
  10. name
    Ji JH
    type
    Author
  11. name
    Garassino MC
    type
    Author
  12. name
    Voitko O
    type
    Author
bibliography ids
  1. nci-bib-3bfd6cdc56d4c2cdc3bd9017
book metadata
content sha256
6c8c112b03650a9b986833aba418abf3ccb129bdc00337e8510d9151b7aa38bf
document type
citation
dois
  1. 10.1016/S1470-2045(20)30539-8
electronic publication date
display
2020 Dec 4
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:33285097
immutable id
pubmed:33285097@6c8c112b03650a9b986833aba418abf3ccb129bdc00337e8510d9151b7aa38bf
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
51-65
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Mar;22(3):e83. doi: 10.1016/S1470-2045(21)00008-5.
    note
    Source null
    related pmid
    33662291
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Mar;22(3):e84. doi: 10.1016/S1470-2045(21)00083-8.
    note
    Source null
    related pmid
    33662292
    relationship
    Comment in
outcomes validated
false
pmid
33285097
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
cfbe4f01cb2910efd7a782f87d601e5020f234d10c16494589210825fbd9b9a2
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2021 Jan
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33285097/
title
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

Preserved source evidence · Not medical advice